Up-regulation of annexin A2 (ANXA2) is associated with progression and metastasis of high-grade glioma [10] and hepatocellular [11], pancreatic [12], colorectal [13], lung [14, 15], and breast cancers [16], whereas down-regulation of ANXA2 occurs in patients with head and neck squamous cell carcinoma [17, 18], esophageal squamous cell carcinoma [19], and prostate cancer [20], indicating that ANXA2 may be a useful marker for the prognosis of these patients. The gene discussed is ANXA2; the disease is prostate carcinoma.